Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer

Background Hypofractionated stereotactic body radiation therapy (SBRT) has been advanced as monotherapy for low-risk prostate cancer. We examined the dose distributions and early clinical outcomes using this modality for the treatment of intermediate-risk prostate cancer.